Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia
Royun Park, Seoyoung Kim, Euitae Kim
Psychiatry Investig. 2020;17(11):1158-1165.   Published online 2020 Nov 18     DOI: https://doi.org/10.30773/pi.2020.0306
Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia
Deepak K. Sarpal, Annie Blazer, James D. Wilson, Finnegan J. Calabro, William Foran, Charles E. Kahn, Beatriz Luna, K.N. Roy Chengappa
Schizophrenia Research.2022; 243: 170.     CrossRef
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia
Steven M. Paul, Samantha E. Yohn, Michael Popiolek, Andrew C. Miller, Christian C. Felder
American Journal of Psychiatry.2022;[Epub]     CrossRef
Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia
Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, Mirko Manchia, Vincenzo De Luca, Felice Iasevoli, Christoph U. Correll
Pharmacology & Therapeutics.2022; 236: 108236.     CrossRef
Reliability of the Clozapine:N-Desmethylclozapine (CLZ:NDMC) Ratio
Shirlee Daniela Solomon, Valerie Powell, Marcos Sanches, Carol Borlido, Leah Burton, Vincenzo De Luca, Tarek Rajji, Gary Remington
Schizophrenia Bulletin Open.2021;[Epub]     CrossRef
Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review
Rafaella Georgiou, Demetris Lamnisos, Konstantinos Giannakou
Frontiers in Psychiatry.2021;[Epub]     CrossRef